TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 08, 2019 06:45 ET
|
TCR2 Therapeutics
Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20Leading clinical sites participating in the TC-210...
TCR² Therapeutics to Participate in Upcoming Conferences in August
August 06, 2019 16:05 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires
August 06, 2019 06:45 ET
|
TCR2 Therapeutics
Expansion of leadership team to support clinical trials with an emphasis on manufacturing, IND enablement and development of next generation of TRuC-T cells CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE...
TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210
July 31, 2019 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...